Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 16, Issue 1, Pages 43-51
Publisher
Informa UK Limited
Online
2014-12-09
DOI
10.4161/15384047.2014.986967
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic cancer genomics
- (2014) David K Chang et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer
- (2014) Alakesh Bera et al. PLoS One
- The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytoametry
- (2013) Maria Watson et al. CYTOMETRY PART A
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- Evolution and dynamics of pancreatic cancer progression
- (2013) S Yachida et al. ONCOGENE
- Cell motility and drug gradients in the emergence of resistance to chemotherapy
- (2013) A. Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heterogeneity and Targeting of Pancreatic Cancer Stem Cells
- (2012) V. R. Penchev et al. CLINICAL CANCER RESEARCH
- Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
- (2012) Y. Cui et al. CLINICAL CANCER RESEARCH
- Meta-Analysis of Gene Expression Signatures Defining the Epithelial to Mesenchymal Transition during Cancer Progression
- (2012) Christian J. Gröger et al. PLoS One
- Notch Signaling Activated by Replication Stress-Induced Expression of Midkine Drives Epithelial-Mesenchymal Transition and Chemoresistance in Pancreatic Cancer
- (2011) C. Gungor et al. CANCER RESEARCH
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704
- (2011) J J Farrell et al. PHARMACOGENOMICS JOURNAL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Advanced pancreatic carcinoma: current treatment and future challenges
- (2010) Anastasios Stathis et al. Nature Reviews Clinical Oncology
- Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells
- (2009) Y. Li et al. CANCER RESEARCH
- Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
- (2009) Z. Wang et al. CANCER RESEARCH
- Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
- (2009) T. Arumugam et al. CANCER RESEARCH
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma
- (2008) S.-S. Liau et al. CLINICAL CANCER RESEARCH
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started